Optellum, Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

tim.hodson

Thu, 04/17/2025 – 16:25

April, 15, 2025 — Optellum  has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and precision lung cancer care. Under the agreement, Optellum will apply its AI-powered imaging and clinical decision support platform to evaluate the real-world impact on patient outcomes.
Lung cancer remains the leading cause of cancer-related deaths worldwide, often going undetected until it reaches an advanced stage. Late-stage diag…

Read the full article on itnonline.com